NUCLEOSIDE INHIBITORS OF RNA-POLYMERASE HCV NS5B, METHODS FOR PRODUCTION AND USE THEREOF Russian patent published in 2015 - IPC C07D249/10 C07H19/56 C07D401/04 C07F9/6558 C07F9/44 C07H19/10 A61K31/7068 A61K31/664 A61K31/665 A61K31/7056 A61K31/4196 A61P31/14 

FIELD: chemistry.

SUBSTANCE: invention relates to C₃alkyl ethers (S)-2-{[(2R,3R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-4,4-difluoro-3-hydroxy-tetrahydrofuran-2-ylmethoxy]phenoxy-phosphoryl amino}-propionic acid of general formula 1 and pharmaceutically acceptable salts thereof. The compounds have properties of nucleoside inhibitors of RNA-polymerase HCV NS5B and can be used to treat and prevent viral diseases such as hepatitis C. In formula R¹ is C₁-C₄alkyl. A pharmaceutical composition based on a compound of formula 1 may further contain an inhibitor of RNA-polymerase NS5A, such as Ribavirin, Ribamidin or methyl ether hydrochloride [(S)-1-((S)-2-{5-[4-(4-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)pyrrolidin-2-yl-3H-imidazol-4-yl]buta-1,3-diinyl)phenyl]-1H-imidazol-2-yl}pyrrolidin-1-carbonyl)-2-methyl-propyl]}-carbamic acid (AV-4025).

EFFECT: high output.

10 cl, 1 tbl, 12 ex